Differential regulation of TROP2 release by PKC isoforms through vesicles and ADAM17

Tim M Wanger, Sharon Dewitt, Anne Collins, Norman J Maitland, Zaruhi Poghosyan, Vera Knäuper

Research output: Contribution to journalArticlepeer-review


TROP2, a cancer cell surface protein with both pro-oncogenic and anti-oncogenic properties is cleaved by ADAM17. ADAM17 dependent cleavage requires novel PKC activity which is blocked by the ADAM10/ADAM17 inhibitor GW64 as well as by the PKC inhibitor Bim-1. Full length TROP2 release is induced by classical PKC activation and blocked by Gö6979, without affecting ADAM17 dependent TROP2 cleavage. Full length TROP2 is released in ectosomes, as inhibition of endocytosis did not prevent release. Inhibition of the atypical PKC isoform PKCζ stimulated metalloproteinase dependent N-terminal alternative TROP2 cleavage. The resulting alternative TROP2 cleavage product remains membrane associated via a disulphide bond, but is released in microvesicles with an average size of 107nm. Inhibition of endocytosis following PKCζ inhibition prevented alternative cleavage and release of TROP2, suggesting that these events require endocytic uptake and exosomal release of the corresponding microvesicles. The alternative TROP2 cleavage product was also found in PC3 cell lysates following deglycosylation, and may represent a novel biomarker in prostate cancer.

Original languageEnglish
Pages (from-to)1325-1335
Number of pages11
JournalCellular Signalling
Issue number7
Publication statusPublished - Jul 2015

Bibliographical note

Crown Copyright © 2015. Published by Elsevier Inc. All rights reserved.

Cite this